Effects of 1‐year treatment with canagliflozin on body composition and total body water in patients with type 2 diabetes

To characterize the long-term changes in body composition associated with sodium-glucose cotransporter-2 (SGLT2) inhibitors.In this multicentre, single-arm, open-label study, 107 patients with type 2 diabetes were treated with canagliflozin 100 mg, as add-on therapy, for 12 months. Body composition was measured with a body composition analyser (T-SCAN PLUS) using the impedance method to prospectively analyse changes in body components, including...